Interleukin Genetics has appointed experts to its clinical advisory board to advise the company on clinical programs that demonstrate the clinical benefits of targeted prevention and treatment of periodontitis.
Board members include the following:
- Sir Gordon Duff, MD, PhD, St. Hilda's College, University of Oxford
- Gary Armitage, DDS, University of California, San Francisco School of Dentistry
- William Giannobile, DDS, University of Michigan School of Dentistry
- Steven Offenbacher, DDS, PhD, University of North Carolina School of Dentistry
- Panos Papapanou, DDS, PhD, Columbia University College of Dentistry
- Mariano Sanz, MD, DDS, University of Complutense of Madrid
"We are extremely pleased to bring together a 'dream team' of international experts at the intersection of systemic and oral health, to advise Interleukin Genetics on building evidence and care pathways, and the dissemination of practical clinical approaches to capture medical value," stated Kenneth Kornman, DDS, PhD, president and chief scientific officer of Interleukin Genetics, in a press release.
